Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179)
:2179
Want to see HK:2179 full AI Analyst Report?
2179 Stock Chart & Stats
HK$4.18
-HK$0.53(-6.02%)
At close: 4:00 PM EST
HK$4.18
-HK$0.53(-6.02%)
Day’s Range― - ―
52-Week RangeHK$3.40 - HK$9.29
Previous CloseN/A
Volume13.00K
Average Volume (3M)18.23K
Market Cap
HK$3.87B
Enterprise ValueHK$2.66B
Total Cash (Recent Filing)HK$351.99M
Total Debt (Recent Filing)HK$638.75M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding458,092,160
10 Day Avg. Volume1,300
30 Day Avg. Volume18,233
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)2.70
Price to Sales (P/S)153.96
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving LeverageA meaningful reduction in debt-to-equity reduces immediate financial strain and interest burdens, improving liquidity flexibility. Over the next several months this stronger leverage profile lowers refinancing pressure and gives management more runway to fund R&D, clinical programs, and commercial supply build-outs without urgent capital raises.
Integrated R&D-to-manufacturing ModelVertical capabilities spanning research, development, manufacturing and commercialization create durable operational advantages for a biotech vaccine developer. Owning manufacturing and supply reduces reliance on third parties, supports regulatory filings and product supply continuity, and strengthens long-term commercial execution prospects.
Improving FCF TrendAn improving free cash flow trajectory, even from negative levels, signals progress in cost control, operational efficiencies, or shifting revenue mix. If sustained, this trend can reduce cumulative cash burn and the frequency/size of future external funding rounds, materially improving financial durability over a multi-quarter horizon.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flows indicate the business regularly consumes cash to fund operations and investment. This creates ongoing reliance on external financing, raising dilution and refinancing risk. Over months, sustained cash burn constrains investment in commercialization and clinical progress absent new capital.
Volatile And Shrinking Revenue; Negative Gross ProfitA steep revenue decline and negative gross profit point to commercialization, pricing or cost-of-goods issues that undermine margin sustainability. These structural revenue and gross-margin problems reduce visibility into future cash generation and impede the company’s ability to scale profitable commercial operations without substantive remedial actions.
Eroding Asset Base And Negative ReturnsDeclining total assets alongside deeply negative ROE indicate the company is eroding capital rather than compounding value. This weak capital trajectory constrains capacity to invest in R&D and manufacturing, diminishes resilience to operational setbacks, and signals heightened long-term risk for equity holders if trends persist.
Jiangsu Recbio Technology Co., Ltd. Class H News
2179 FAQ
What was Jiangsu Recbio Technology Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Recbio Technology Co., Ltd. Class H lowest stock price was HK$3.40 and its highest was HK$9.29 in the past 12 months.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s market cap?
Jiangsu Recbio Technology Co., Ltd. Class H’s market cap is HK$3.87B.
When is Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date?
Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 20, 2026 which is in 91 days.
How were Jiangsu Recbio Technology Co., Ltd. Class H’s earnings last quarter?
Jiangsu Recbio Technology Co., Ltd. Class H released its earnings results on Mar 24, 2026. The company reported -HK$0.498 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.498.
Is Jiangsu Recbio Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangsu Recbio Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Jiangsu Recbio Technology Co., Ltd. Class H pay dividends?
Jiangsu Recbio Technology Co., Ltd. Class H does not currently pay dividends.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate?
Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jiangsu Recbio Technology Co., Ltd. Class H have?
Jiangsu Recbio Technology Co., Ltd. Class H has 458,092,160 shares outstanding.
What happened to Jiangsu Recbio Technology Co., Ltd. Class H’s price movement after its last earnings report?
Jiangsu Recbio Technology Co., Ltd. Class H reported an EPS of -HK$0.498 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.435%.
Which hedge fund is a major shareholder of Jiangsu Recbio Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2179
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jiangsu Recbio Technology Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.26%
12-Months-Change
Fundamentals
Return on Equity
-137.11%
Trailing 12-Months
Asset Growth
-4.96%
Trailing 12-Months
Company Description
Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
SinoMab Bioscience Ltd.
―